Abstract: Beta-glucans ( -glucans), naturally occurring polysaccharides, are present as constituents of the cell wall of cereal grains, mushrooms, algae, or microbes including bacteria, fungi, and yeast. Since Pillemer et al. first prepared and investigated zymosan in the 1940s and others followed with the investigation of -glucans in the 1960s and 1970s, researchers have well established the significant role of -glucans on the immune system relative to cancer treatment, infection immunity, and restoration of damaged bone marrow. However, information on their biological role in anti-metastatic activity remains limited. As an immunomodulating agent, -glucan acts through the activation of innate immune cells such as macrophages, dendritic cells, granulocytes, and natural killer cells. This activation triggers the responses of adaptive immune cells such as CD4 + or CD8 + T cells and B cells, resulting in the inhibition of tumor growth and metastasis. Reports have shown that -glucans exert multiple effects on cancer cells and cancer prevention. However the mechanisms of their actions appear complex due to differences in source, chemical structure, insufficiently defined preparation, and molecular weight, hence the inconsistent and often contradictory results obtained. This review is focused on the potential of -glucans as anti-metastatic agents and the known mechanisms underlying their biological effects.
INTRODUCTION
Scientists have considered beta-glucans ( -glucans) as an important constituent for decades. Current knowledge about the molecular interaction of -glucans with various cell types comes from the first investigative studies conducted with zymosan in 1941. Zymosan, a mixture of polysaccharides obtained from yeast, consists of a variety of substances including mannans, glucans, glucosamine, and glycoproteins; therefore is not ideal for the investigation of -glucan-specific activities [1] .
Humans have recognized and consumed -glucans, consisting of half the mass of fungal cell wall, as potent immunological stimulators for thousands of years, especially in China and Japan [2] [3] [4] . Caregivers have administered -glucans orally for treatment of human diseases historically with no reports of adverse effects. In addition, the inexpensive -glucans appear to act by modulating the immune system.
As -glucans are not synthesized in humans, the immune system recognizes these compounds as non-self molecules, inducing both innate and adaptive immune responses [5] . The antitumor activity of -glucans was first demonstrated around 50 years ago, and since the 1980s several studies on animals have reported on the remarkable effects of -glucans on a range of tumors [6, 7] . Despite the limited studies on the effect and action mechanism in the role of -glucans, this review discusses the available literature on the potential anti-metastatic effect of -glucans and the probable mechanisms underlying their biological effects.
MURINE MODELS
Several investigations have reported on the anti-metastatic effect of -glucans by using the murine metastasis model. Notably, Inobata et al. demonstrated that schizophyllan decreased the frequency of metastasis and prolonged the life span of mice imbedded with Lewis lung cancer cells. In this model, schizophyllan increased the infiltration of macrophages and T cells in the local tumor and lung nodulation [8] . Earlier, we reported the inhibitory effects of -glucans (IS2) purified from mutated Saccharomyces cerevisiae (S. cerevisiae) on lung metastasis of colon 26-M3.1 carcinoma; IS2 induced splenocyte proliferation, tumoricidal activity, and cytokines production in peritoneal macrophages and induced natural killer (NK) cell cytotoxicity but did not directly affect cytotoxicity on colon 26-M3. 1 
cells in vitro.
We further confirmed toll-like receptor (TLR)4 and MyD88 as crucial molecules and signal mediators for these -glucans [9] [10] . Zhong et al. applied human lung cancer cells as a xenograft model in mice and achieved long-term survival when they treated mice with a combination of monoclonal antibodies and -glucans through the complement deposition and neutrophils infiltration [11] .
ANTI-METASTATIC EFFECT OF BETA-GLUCANS FROM MUSHROOMS
Several research groups carried out studies on the antimetastatic effect of -glucans from mushrooms. Kodama et al. isolated grifolan (GRN, Fig. 1A) , a -1,6 glucan with -1,3 branched chains, from Grifola frondosa (Maitake mushroom), and reported that GRN containing Maitake D-fraction (PDF) hindered metastatic progress and lessened the expression of tumor markers examined in tumor patients [12, 13] . The acid-insoluble PDF is alkali-soluble and hot water-extractable. This fraction also has been reported to have anti-tumor and anti-metastatic activity by oral and systemic administration in cancer patients as well as tumor-bearing mice. Activation of immune cells such as macrophages, dendritic cells (DCs), NK cells, and T cells participated in this improvement [12] [13] [14] [15] . Reports have also shown GRN to inhibit tumor growth and improve significant symptoms when administered in breast and lung cancer patients. Furthermore, in treatment along with chemotherapy, GRN enhanced immune-competent cell activities 1.2-1.4 times, compared with chemotherapy alone, by enhancing the immune system through activation of macrophages, T cells, and NK cells [12] [13] [14] [15] [16] .
Chihara et al. purified lentinan (Fig. 1B) , a glucan extracted from Lentinus edodes, in 1970 [17] . Intraperitoneal (i.p.) administration of lentinan induced cytolytic activity of macrophages against metastatic tumor cells such as Lewis lung carcinoma in an in vivo animal models and two human melanomas, and its prophylactic treatment in murine proved effective in tumor metastasis [17, 18] . In addition, a cancer patient diagnosed as having gastric cancer with multiple hepatic metastases showed a 99% reduction in hepatic metastases when lentinan was coadministered with anti-cancer drugs for 4 months post surgery [19] .
Water-soluble -glucans, with a -1, 3 glucan branched by 1,4 or 1, 6 branched chains, purified from Ganoderma lucidum (G. lucidum) have shown antitumor activity in mice [20] . These soluble -glucans enhance the function of monocytes, macrophages, DCs, neutrophils, and NK cells [21] . Jang et al. reported that the ethanol fraction of G. lucidum has an inhibitory effect on matrix metalloproteinase (MMP)-2 and MMP-9 activities in human gastric carcinoma cells suggesting that administration of soluble -glucans can inhibit tumor-induced angiogenesis and metastasis [22] .
In mice, oral supplementation of -glucans extracted from Agaricus blazel (A. blazel) reduced spontaneous pulmonary metastasis of 3LL cells and peritoneal disseminated metastasis of HRA cells and inhibited the growth of these metastatic tumors in lung or peritoneal cavity [23] . Oshiman et al. further supported the results that oral administration of -1, 6-D-polyglucose of A. blazel showed a significant regression of inoculated tumors in mice [24] . Niu et al. ascertained that anti-tumor activity in tumor-bearing mice by linear -1, 3 glucans isolated from A. blazel resulted from the activation of NK cells and production of cytokines [25] .
Dong et al. isolated HEP3, a -D-glucan slightly soluble in water, from the alkaline extract of the fruiting bodies of Hericium erinaceus (H. erinaceus) in 2006 [26] . Lee et al. reported that theglucan from this mushroom activated macrophage function by increasing the production of nitric oxide and expression of interleukin (IL)-1 and tumor necrosis factor (TNF)- [27] . In addition, Kim et al. reported that systemic injection of the water and water/ethanol extracts containing -glucan significantly reduced tumor weights of CT-26 colon cancer cells in mice by activation of macrophages and inhibition of angiogenesis, suggesting that H. erinaceus derived -glucans inhibit tumor metastasis [28] .
Schizophyllan (SPG, Fig. 2A) , a highly purified -1, 3-Dglucan from the culture broth of Schizophyllum commune (S. commune) Fries, decreased the frequency of lung metastasis and prolonged the life span of mice in a spontaneous model using Lewis lung cancer cells [29] . in C3H/He mouse models inoculated with squamous-cell carcinoma NR-S1. They further reported these effects occurred through activation of immune cells and production of cytokines such as TNF-and interferon (IFN)- [31] [32] [33] . These reports suggest the availability of -glucans isolated from mushrooms for coadministration with other anti-cancer agents to treat metastasis.
Jones et al. purified a -1, 3 branched 1, 6 glucan (SSG, Fig. 2B ) from Sclerotinia sclerotiorum (S. sclerotiorum) [34] . Administration of SSG (oral and i.p.) inhibited experimental pulmonary metastasis of Lewis lung carcinoma through activation of macrophages to enhance phagocytic and lysosomal enzyme activity, active oxygen secretion, and cytokine production [35, 36] . Others purifiedglucans from various mushrooms such as Auricularia auriculajudae and Cordyceps sinensis. An investigation of the administration of these glucans exhibited anti-tumor activity in mouse models but studies have yet to examine this anti-tumor metastasis activity thoroughly [37, 38] . Table 1 summarizes solubility of -glucans from different sources of mushrooms and yeasts.
Besides -glucans, mushrooms contain potential effective anticancer compounds such as polysaccharides, polysaccharidebound protein and steroids. Several researchers reported the anticancer effects of these compounds having cytotoxicity and antioxidant, anti-angiogenic, and immuno-modulating activity. Thus these compounds may induce synergistic anti-cancer effects when administered with anti-cancer drugs as well as radiotherapy [39, 40] .
ANTI-METASTATIC EFFECT OF BETA-GLUCANS FROM OTHER SOURCES (YEASTS)
Limited investigation of the -glucans isolated from S. cerevisiae has been reported for its anti-metastatic activity, even though there is little evidence whether these glucans inhibit cancer growth by immunomodulation or blocking metastasis [9] . Theglucans from different sources have specific characteristics in structure and conformation, thus biologic activity depends on their specific characteristics [41, 42] . Whole yeast -glucan particles can activate DCs and stimulate Th1 dominant immune response, leading to anti-tumor activity. Research shows that administration of yeasts-derived particulate -glucans activates innate and adaptive immune response and down-regulate immunosuppressive cells to delay tumor progression [41] .
In contrast, soluble, yeast-derived 1, 3--glucan (PGG; betafectin) shows little evidence in stimulating immune system and inhibiting tumor cell growth and metastasis [43, 44] . We reported that soluble -glucans (IS-2) purified from mutated S. cerevisiae inhibited lung and liver tumor metastasis in murine models [9] . Yeast-derived particulate -glucans have shown to bind dectin-1 receptor and activate DCs and macrophages to secrete proinflammatory cytokines such as TNF-, IL-12, IL-6 [41, 45] .
Zymosan (Fig. 3A) , a cell wall extract of S. cerevisiae, contains nonuniform branches and backbone units of -glucans as well as mannans, mannoproteins, and chitin. Many researchers have carried out the effect of -glucans with zymosan and have verified their anti-oxidant and immune functions, leading to an anti-tumor activity of S-180 tumor-bearing mice [46, 47] .
COMBINED EFFECT OF BETA-GLUCANS ON ANTI-METASTATIC ACTIVITY WITH OTHER THERAPIES
Trials for combination therapy on tumor growth and metastasis carried out with the murine model or human metastatic cancer patients used -glucans with other treatments such as cytokines, radiation, and antibodies. Among these trials, combinations with antibodies proved the most prominent and other authors mentioned in this review. Further combination trials with chemotherapy or cytokines include schizophyllan with local irradiation using murine model in 1992. This combinatorial treatment showed remarkable inhibition of pulmonary metastasis from the early stage of tumor growth [48] .
A combination of -glucan and IFN-in an experimental liver metastasis model almost entirely inhibited the growth of liver metastasis [49] . A combination trial of other cytokine IL-2 withglucans against a metastatic murine model showed a synergic antimetastatic effect and prolonged survival of cancer cell-inoculated mice. CD4
+ and CD8 + cells as well as NK cells and macrophages were reported to be involved in these synergistic effects [30, 50, 51] .
Mushiake et al. explored the combined treatment of lentinan with anticancer drug fluoropyridine and found that this combined treatment could augment the survival period of colon-26-bearing mice. This combined treatment found infiltration into tumor sites and augmentation of functional DCs in vivo and in vitro. Splenic DCs harvested from combined treated mice showed more potent T [46, 47] cell proliferation activity than that of DCs from mice treated with fluoropyridine alone. Furthermore, the activity of cytotoxic T lymphocytes (CTLs) in splenocytes of this combined treatment was more specific and potent than that of CTLs from mice treated with fluoropyridine alone. Moreover, the study found that athymic mice do not share the same prolonged survival effect. The above findings indicated that DC activation can induce T cell proliferation and CTL activation [52] . Harnack et al. and our group reported the potential availability of -glucan in a combination therapy with anti-cancer drugs to minimize their side effects [53, 54] .
CLINICAL TRIALS OF BETA-GLUCANS ON HUMAN METASTASIS
Although several reports have discussed on the effect ofglucans on clinical cancer treatment and have shown possible treatment benefits, the reports and data dealing with the effects on metastasis remain preliminary and controversial [55] .
Okuyama et al. conducted the first clinical trial with -glucans against metastasis in 1985. This group used lentinan as -glucan for a subsidiary chemotherapy measure in patients with post-operation of gastric cancer with liver metastasis and showed an increased survival rate compared to results of treatment using only 5-fluorouracil (5-FU) plus mitomycin [56] . Recent studies revealed lentinan was effective in patients with advanced pancreatic, colorectal, and gastric cancers [57] [58] [59] .
The effect of lentinan on lymphocyte subset in peripheral blood, lymph nodes, and tumor tissues in gastric cancer patients with or without lymph node metastasis was also investigated. The study revealed no significant changes in the lymphocyte subsets, such as CD3 
, and CD14 (LeuM3) cells appeared in tumor-infiltrating lymphocytes without metastasis. In addition, lentinan was reported to enhance T cell functions in cancer patients [60, 61] . These data indicate the possible role of T cells by -glucan treatment in advanced cancer patients.
Studies have looked at the effect of oral administration ofglucans on peripheral blood monocytes and their expression of activation markers in advanced breast cancer patients. Oral administration of -glucans for 2 weeks affected the proliferation and activation of peripheral blood monocytes, increased the expression of CD95 and CD45RA + , and activated monocytes. This short-term investigation (only 2 weeks), showed that oral -glucan administration seems to stimulate proliferation and activation of peripheral blood monocytes in advanced breast cancer patients [62] .
In another clinical studies, -glucans proved effective in metastatic cancer and improved the survival rate of patients treated with a combination chemotherapy or hormonochemotherapy [12, 63, 64] . Shimizu et al. reported that CD4-, CD3-stained cells, and IL-2R-stained cells tend to increase in the metastatic pelvic lymph nodes in patients with advanced cervical cancer receiving preparative schizophyllan [65] .
Despite the observed effect of -glucans on cancer metastasis, the data proved contradictory and scarce due to the limitation of cases and investigation in the clinical study. Furthermore, the proposed mechanisms from these authors were based on in vitro and animal experiments. Therefore, future efforts should go toward studies with the generalized structure of -glucan and well-designed protocols to verify the clinical efficacy of -glucan alone or in combination.
MECHANISMS OF ANTI-METASTATIC ACTION BY BETA-GLUCANS -glucans at Innate and Adaptive Immune System
Most -glucans are considered as non-digestible carbohydrates and are fermented to various degrees by the intestinal microbial flora [66] [67] [68] . Further, -glucans did not show any action on apoptotic pathways and no direct effect on telomerase [69] . Therefore, it has been speculated that -glucan actions in immune cells or immunomodulatory properties may be partly attributed to their functional effects [2, 70] 
Fig. (3). Chemical structure of Zymosan (A), Laminarin (B) and Scleroglucan (C).
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immunomodulators, and these in turn activate adaptive immune cells such as T cells and B cells [18, [71] [72] [73] [74] [75] . -glucans enhanced IFN-production from tumor-infiltrating T cells, CTL responses and DC infiltration within tumors, leading to reduced tumor burden [76, 77] . As a consequence, both innate and adaptive responses can be modulated by -glucans in their anti-metastatic actions. Many investigations have undertaken on the immune and antitumor activity of lentinan, a -D-glucan derivate isolated from L. edodes, and reported that this compound not only acts as T cell oriented adjuvant through innate immune cell activation but having augmented activities of NK cells, lymphokine activated killers (LAKs), and CTLs [78, 79] . Lentinan also accelerates the infiltration of granulocytes into target tissues and activates secretion of active oxygen and production of cytokines as well as cytotoxicity in peritoneal macrophages against metastatic tumors. Investigators have reported on the role of the complement system together with macrophage activation by lentinan [80] . Schizophyllan structurally related to lentinan activates macrophages in vitro and in vivo, leading to augmentation of T cell activation, but do not directly activate T cells [81, 82] . In addition, glucan SSG from S. sclerotiorum induces the development of Th1 cells via the IL-12 pathway and stimulates Th1 cells to produce IFN-, which activates macrophages [83] . In animal studies, the orally administered specific backbone 1-3 linear and -glycosidic chain of -glucans enter the proximal small intestines as undigested form. Where in some are captured by the macrophages via the dectin-1 receptor, and transport them to the spleen, lymph nodes, bone marrow and endothelial reticular system. The large -1, 3-glucans in the macrophages are degraded into smaller soluble -1, 3-glucan fragments, which are released from macrophages and taken up by other immune cells through complement receptors 3 (CR3) expressed on neutrophils and NK cells, leading to the killing of opsonized tumor cells after they were recruited to complement activation sites coated with monoclonal antibodies [69, 84] .
We can also consider administration of soluble -glucans because they can be delivered directly to the CR3 on circulating granulocytes [84] . Soluble -glucans such as laminarin (Fig. 3B) and scleroglucan (Fig. 3C) can be directly bound and internalized by intestinal epithelial cells and gut-associated lymphoid tissue (GALT) cells [85] . This internalization does not take place through dectin-1 alone, rather, dectin-1 and TLR2 are accountable for uptake of soluble -glucans by GALT cells. The use of thymectomized mice or anti-lymphocyte serum has elucidated the role of T cells and lymphocytes in these immune responses. This group further suggested the function of lentinan to restore humoral immune responses [86] . Li et al. examined the trafficking of orally administered particulate -glucans and their process in vivo. -glucans trafficked into spleen and lymph nodes and activated DC that captured dying tumor cells, leading to the expansion and activation of antigen-specific CD4 + and CD8 + T cells [76] .
Qi et al. compared functional characteristics between particulate and soluble -glucans and suggested rational design of immuno-therapeutic protocols. They reported that yeast-derivedglucans activate DCs and macrophages via dectin-1. By using dectin-1 knock out mice, they found particulate -glucans but not soluble -glucans activate DCs that promote Th1 and CTL priming and differentiation. However, soluble -glucans were found to bind DCs and macrophages via dectin-1 independently and did not activate DCs. Although soluble -glucans had no therapeutic effect, they augmented antibody-cotreatment efficacy via complement activation pathways [41] .
Mishiake et al. suggested chemoimmunotherapy combined with -glucans in vivo. Anticancer drugs combined with lentinan prolonged the survival period through augmentation of DC infiltration into the cancer site, T cell proliferation and CTL activity [52] .
Signal Events Involved in Anti-metastatic Action of -glucans
Generally, polysaccharides are considered as classic T-cell independent antigens that do not elicit cell-mediated immune responses. Likewise, glucans are thought to mediate their effects via interaction with membrane receptors on innate immune cells such as macrophages, neutrophils, and NK cells [1] . To date, research has identified six categories of -glucan receptors supposed to mediate these activities. These include, dectin-1; TLR-2 and TLR4; CR3 (CD11b/CD18); lactosyl ceramide (LacCer); glycosphingolipid; and selected scavenger receptors [1, 70, [87] [88] [89] [90] [91] (Table 2, Fig. 4) .
Among these receptors, dectin-1 commonly expresses on macrophages, neutrophil lineages, DCs, and some T cells but not on NK cells [92] [93] [94] [95] . Evidence suggests that dectin-1 is most important in the activation of innate immune responses in macrophages as mediating activation of phagocytosis and production of cytokines [96] [97] [98] . Dectin-1 and SIGN-related 1(SIGNR1) are known to be the major receptor for the -glucan-dependent non-opsonic recognition of zymosan on macrophages, and TNF-production was induced by these receptor molecules in vitro [72, 95, 99, 100] . In vivo evidence by using dectin-1 -/-mice also revealed dectin-1 as the major receptor for zymosan and involved in leukocyte responses to -glucan [98] .
Investigators have shown TLR-2 as involved in the response to zymosan [73, 101] . They further investigated the role of TLR-2 associated with dectin-1 for recognition of -glucan. Dectin-1 synergized with TLR-2 induced production of IL-2, IL-10, IL-12 and TNF-. The authors additionally elucidated the role of Syk kinase in the production of IL-2 and IL-10 from DCs [77, [102] [103] [104] [105] . Interestingly, Syk plays a major role in the induction of IL-2 and IL-10 in DC, and this induction requires ERK MAP kinase but remains unaffected by MyD88 deficiency, indicating the important role of dectin-1 in DC from -glucan stimulation. Furthermore, Brown et al. suggested that zymosan can induce the co-localization of dectin-1 with TLR-2 to make a signal complex [39] . But proinflammatory cytokine production or phagocytosis by macrophages can occur by dectin-1 only without TLR [94, 106, 107] . The action mechanism of -glucan on cancer includes the C3 fragment of complement and antibodies [108] . The 2 integrin, CR3 expresses mainly on neutrophils, monocytes, NK cells, and lymphocytes, but not macrophages [69, 92] . Zymosan increased NK cell-mediated killing of tumor cells via activation of CR3 [6, 109] . Among these, CD11b, the subunit of CR3 regulates both cytotoxic and adhesion functions of Mac-1/CR3 [1] . The possible role of scavenger receptors, if any, in the biological effects mediated byglucans remains unknown, and has no evidence that they play major roles in anti-cancer activity [4, 110] .
LacCer located in neutrophil and endothelial cells, was supposed to have the role for signal transduction platforms for CD11b/CD18-dependent neutrophil phagocytosis, but the role played by -glucans in metastasis remains unclear [111] .
Sphingolipid as component of lipid rafts on plasma membrane was supposed to mediate signal complex together with dectin-1 or TLR2/4, leading to activation of cells through these receptors [112] [113] [114] [115] . Considering the results of the above-mentioned literature, we can assume dectin-1 as the main receptor for -glucan signaling, but research has not yet determined its role in anti-metastasis in vivo.
Investigations concerning the interrelation between the chemical structure of -glucan and its antitumor effects suggested the major significance of the functional importance of water solubility and location of substitute groups of -glucan on antitumor activity. Furthermore, the biological effects of -glucans differ in molecular weight (MW) and chemical modifications of degree of branching, polymer length and tertiary structure. In general, large MW or particulate -glucans can more effectively activate phagocytic activity, and stimulate proinflammatory mediator production [116, 117] . However, different groups reported contradictory data [118] [119] [120] . Likewise another group considered soluble -glucans as stronger immunostimulators than insoluble ones [121] [122] [123] [124] . Intermediate or low-MW -glucans possess biological activity in vivo, but their in vitro activities were less clear [125] . Smaller molecular size -glucan binds to CR3 in NK cells, and that of large molecular size binds dectin-1 and TLRs in macrophages and DCs [75] . In addition, O'Brien elucidated the role of CR3 for signal mediators from soluble -glucan and showed the conformational change of CR3 and functional proteomics profile after the binding of -glucan on CR3 [126] . Cramer et al. examined the role of signal mediators from fungal -glucan particles to secrete proinflammatory cytokines by resident macrophages and reported that dectin-1 and CR3 were not crucial for cytokine secretion but partially dependent on MyD88 pathway. This indicates that the receptor and signal pathway for -glucan differ on source of -glucan and cell origin [45] . Further, -glucan can make a single or triple helical conformation in solution by hydrogen bonds between polymer chains. At least one study regarded those with a triple helical configuration as more powerful immunomodulators [118] . However, their individual anti-tumor activities with different branching frequencies have not been studied. Although physico-chemical studies of -glucan with different structures and affinity study with different sources were examined, information on the structural variations of -glucans on anti-metastasis is limited [120] .
CONCLUSIONS
In summary, -glucans prime the innate immune cells such as blood neutrophils, macrophages, DCs, and NK cells, specifically recognizing complement-antibody complexes and killing tumor cells. Binding of -glucan to specific receptors (especially dectin-1, TLR2, and CR3) activates macrophages, leading to increased chemokinesis, chemotaxis, and migration of macrophages. However, no evidence exists on whether these migration activities set the tumor cells in motion and into other tissues resulting in metastasis. While researchers have proved the role of -glucans on anti-metastatic activity and explored the intrinsic mechanisms at cellular and molecular levels, we have insufficient data on whether -glucans inhibit the metastatic progress or protect the cell growth by direct killing or immunomodulating activity. Traditionally, the beneficial effects of -glucans in vitro and in vivo experiments including human clinical trials did not involve single pure -glucan, resulting in conflicting reports from most of the available information on relationships between structure and functions. Controlled experiments and generalized treatments with -glucans require well-defined structure and characterized standards since we have limited reports of clinical trials using purified -glucans for cancer patients. Most of the available evidence comes from in vitro or animal studies and clinical studies have just now begun to appear. Additionally, combination treatments may also prove helpful after detailed preclinical examinations. It is to be noted that the effect and action mechanism of -glucan in vivo can differ markedly according to the structures, MWs, and solution conformations. Further, investigators have yet to clearly understand the metabolic fate of ingested -glucans. Therefore, future studies must follow careful protocols in clinical application of -glucans. Finally, this review offers some hope for future research results to emerge on the role of -glucans as potent anti-metastaic agents.
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